Shanghai Yizhong Pharmaceutical Co. Ltd. Class A

As of June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A carries a market capitalization of 8.31B, placing it among publicly traded companies globally. Its enterprise value stands at 7.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A has 206.70M shares outstanding.

As of June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 102.60. The price-to-sales ratio is 25.03, and the price-to-book ratio stands at 5.57.

As of June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A trades at an EV/EBITDA multiple of 101.28 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 24.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 101.28 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 7.89B versus a market cap of 8.31B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A maintains a current ratio of 13.84, meaning it holds 13.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.68, indicating elevated leverage, while an interest coverage ratio of 249.71 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A posted a return on equity (ROE) of 5.49, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 5.21, measuring how efficiently the asset base is converted into earnings. The company generates approximately 778,316.43 in revenue per employee across its workforce of 421.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.02 indicates how many times Shanghai Yizhong Pharmaceutical Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A recorded an income tax benefit of -2.19M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 77.83M, leaving 80.02M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A's stock has declined approximately 35.89% over the past 52 weeks. The 50-day moving average sits at 39.15, while the 200-day moving average is 47.49.

Over the twelve months ended June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A generated 328.06M in revenue and converted that into 80.02M in net income, yielding earnings per share of 0.39. EBITDA reached 77.94M, while operating income came in at 64.42M.

As of June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A holds 440.90M in cash and equivalents against 25.01M in total debt, resulting in a net debt position of -166.77M. Total book value stands at 1.49B, with working capital of 1.08B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A posted a gross margin of 84.16, reflecting its pricing power and cost economics. The operating margin of 19.64 and net profit margin of 24.39 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of 0.28 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.09, meaning Shanghai Yizhong Pharmaceutical Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shanghai Yizhong Pharmaceutical Co. Ltd. Class A's most recent stock split took place on May 17, 2024 with a 10:13 split ratio.

As of June 30, 2026, Shanghai Yizhong Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 45.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.